Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 20, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transactions executed on July 19, 2006, by the GlaxoSmithKline (US) Trust ("the GSK US Trust") on behalf of participants in the GlaxoSmithKline Share Value Plan:
- Sale of 2,529 Ordinary Share ADRs at a price of $53.89 per ADR.
- Transfer of 5,242 Ordinary Share ADRs to plan participants.
Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the GSK Trust in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: July 19, 2006.
- Transaction Price: $53.89 per ADR.
- Entities Involved: Abacus Corporate Trustee Limited (as trustee) and the GSK US Trust.
- Directors with Interests: Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop.
- Reporting Basis: Notification of changes in interests pursuant to Rule 13a-16 or 15d-16.